Please login to the form below

Not currently logged in


This page shows the latest Keynote-024 news and features for those working in and with pharma, biotech and healthcare.

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

In recently published long-term data from the phase 3 KEYNOTE-024 trial, Keytruda reduced the risk of death by 38% versus chemotherapy at the five-year time point among NSCLC ... In addition, another advanced, PD-1-positive NSCLC monotherapy study of

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
IPG Health Medical Communications

We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...